Brain Iron Chelation with Deferiprone in Parkinson’s Disease
In a randomized, placebo-controlled treatment trial, deferiprone administered to early, levodopa-naive Parkinson’s disease patients over 36 weeks was associated with worsening of their symptoms, in spite of imaging evidence for reduction of iron in the substantia nigra.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.